60 results about "Bone marrow suppression" patented technology

The invention provides a treatment-caused myelosuppression risk early warning method and related equipment, and is applied to the technical field of data processing. The method comprises the following steps: processing multi-modal data information of a target user to generate a target physiological state prediction factor; processing the serum marker feature information of the target user to generate myelosuppression influence factors; processing the living habit information of the target user to generate a myelosuppression risk adjustment factor; processing the myelosuppression influence factor and the myelosuppression risk adjustment factor to generate dynamic risk parameter information of the target user; and processing the target physiological status prediction factor and the dynamic risk parameter information of the target user based on a target large-dose methotrexate bone marrow suppression risk prediction model to generate a bone marrow suppression risk value and a bone marrow transplantation risk level.

The invention discloses a gastric cancer postoperative chemotherapy dynamic intervention method and system based on time point matching, and relates to the technical field of postoperative intervention. Health state data of wearable medical equipment of a gastric cancer postoperative patient is collected; preliminarily dividing the stomach cancer postoperative chemotherapy cycle into a plurality of key physiological time points based on the symptom inflection points, and respectively matching an intervention core problem and a corresponding stomach cancer postoperative chemotherapy intervention scheme for the plurality of key physiological time points; and the postoperative intervention platform analyzes the time period health state data collected by the wearable medical equipment at set time intervals, analyzes the health state data to automatically identify gastric cancer postoperative symptom inflection points, and dynamically matches key physiological time points based on symptom inflection point results. The stomach cancer postoperative treatment disruption rate is reduced, the crisis inflection point recognition accuracy is greatly improved, and the bone marrow suppression early diagnosis rate is greatly improved; the early diagnosis rate of postoperative wound infection of gastric cancer is improved, unnecessary intervention is reduced, and crisis event treatment is accelerated.

The invention relates to the technical field of veterinary chemical drugs, and provides an application of a selenium-rich composition in a drug for preventing bone marrow suppression after chemotherapy of dogs, and the selenium-rich composition comprises nano-selenium-beta-glucan chelate and L-selenium-methyl selenocysteine, the mass ratio of the nano-selenium-beta-glucan chelate to the L-selenium-methyl selenocysteine is 1: (0.3-0.6), and the mass ratio of the nano-selenium-beta-glucan chelate to the L-selenium-methyl The molar ratio of the astragaloside IV to the cobamamide is (5 to 8): 1. Through the synergistic effect of the nano-selenium-beta-glucan chelate and the L-selenium-methyl selenocysteine and in combination with the loading technology of the silicon dioxide mesoporous carrier, the absorption rate of selenium is greatly improved.

The invention discloses a radix astragali, rhizoma polygonati and ligustrum lucidum ait traditional Chinese medicine preparation for treating myelosuppression as well as a preparation method and a detection method thereof. The preparation is prepared from 50-150 parts of radix astragali, 50-150 parts of wine-processed rhizoma polygonati, 25-75 parts of wine-processed ligustrum lucidum ait, 50-150 parts of blanched rhizoma drynariae, 50-150 parts of radix trichosanthis and 25-75 parts of herba epimedii. The optimal extraction process and refining process are screened out based on effective components and pharmacological activity through a large number of tests, and the optimal preparation process of the Shuanghuangliangwhitening oral liquid and other traditional Chinese medicine preparations is obtained through stability investigation and verification. According to the invention, a thin layer chromatography is adopted, the four medicinal materials of astragalus membranaceus, glossy privet fruit, rhizoma drynariae and herba epimedii are respectively subjected to thin layer chromatography research, and methodology research shows that the method is stable and feasible. The invention establishes a content determination method for astragaloside, calycosin-7-glucoside, specnuezhenide and icariin, establishes a quality standard, and has important significance for ensuring the clinical curative effect and safety of astragaloside, calycosin-7-glucoside, specnuezhenide and icariin.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and a use method, and belongs to the technical field of tumor immunotherapy. The invention formulates a non-small cell lung cancer weak chemotherapy and anti-vascular immunity triple treatment scheme based on the combination of a low-dose chemotherapy drug pemetrexed, an immune checkpoint inhibitor and an anti-angiogenesis drug. According to the scheme, low-dose pemetrexed is combined with the anti-angiogenesis medicine and the immune checkpoint inhibitor for use, the optimal synergistic effect can be achieved, meanwhile, the renal toxicity and the myelosuppression risk are remarkably reduced, and the pemetrexed medicine composition is expected to become one of the optimal choices for driving gene negative and PD-L1 positive expression non-squamous NSCLC patients, and has a wide application prospect. The device is suitable for old people or patients with poor physical states; especially for patients with negative driver genes and positive PD-L1 expression, the traditional treatment blank is filled, and clinical data shows that survival benefits are remarkable.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

The invention discloses a traditional Chinese medicine composition for reinforcing qi and nourishing blood and a detection method thereof. The traditional Chinese medicine composition is prepared from ginseng, astragalus membranaceus, Chinese yam, lily, colla corii asini, roasted rhizoma atractylodis macrocephalae, pulp of dogwood fruit, ligustrum lucidum, schisandra chinensis, pericarpium citri reticulatae, rhizoma anemarrhenae, cornu cervi pantotrichum and lycium barbarum. According to the theory of traditional Chinese medicine, the prescription is screened by adopting the theory of treatment based on syndrome differentiation, and the medicines are scientifically and reasonably matched, have the effects of reinforcing qi, nourishing blood, consolidating the body resistance and strengthening the body resistance, and are used for treating shortness of breath, palpitation, lusterless complexion, weakness and weakness caused by deficiency of qi and blood. In addition, the traditional Chinese medicine composition can improve the body immunity of patients with deficiency of qi and blood, and can also be used for reducing adverse reactions such as myelosuppression and thrombocytopenia caused by radiotherapy and chemotherapy. Content determination is carried out through TLC identification and HPLC, and a scientific basis is provided for guaranteeing the clinical quality and effectiveness of reinforcing qi, nourishing blood and strengthening body resistance.

The invention discloses a traditional Chinese medicine composition for treating myelosuppression after radiotherapy and chemotherapy and a preparation method, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine is prepared from the following raw materials: prepared rehmannia root, suberect spatholobus stem, morinda officinalis, pulp of dogwood fruit, dendrobe, wine-processed desert cistanche, black prepared aconite root, schisandra chinensis, cinnamon, donkey-hide gelatin beads, rhizoma polygonati, mangnolia officinalis, endothelium corneum gigeriae galli, poria cocos, radix ophiopogonis, rhizoma acori graminei, fructus amomi, ginger, jujube and ginseng. Aiming at the core problem of myelosuppression, namely imbalance of qi, blood, yin and yang, careful medicine compatibility is carried out, and the traditional Chinese medicine aims at comprehensively nourishing qi, blood, yin and yang of patients, so that the traditional Chinese medicine is suitable for people suffering from myelosuppression, reduction of three lines of blood cells, weakness and the like caused by various reasons.

The application discloses a high-safety tumor treatment preparation based on a prodrug-enzyme-neutralizing antibody three-system, and a preparation method and application thereof. The preparation comprises three core components: (a) a prodrug, which is coupled by an anti-tumor drug (such as doxorubicin) and cephalosporin; (b) an activating enzyme, such as beta-lactamase, which is specifically expressed in the tumor by phage, catalyzes the hydrolysis of the prodrug, and releases the active drug; and (c) a neutralizing antibody, such as an anti-doxorubicin monoclonal antibody, which can specifically bind and neutralize the active drug overflowing into the blood circulation. The application first integrates the precise killing strategy of "prodrug-local activation" and the safety strategy of "neutralizing antibody-systematic protection" into a complete treatment closed loop, utilizes the "differential neutralization" characteristics of the anti-doxorubicin antibody, effectively protects normal tissues from toxic damage under the premise of not affecting the local efficacy of the tumor, and significantly improves the therapeutic index of the chemotherapy drug, reduces the side effects such as cardiotoxicity and bone marrow suppression, and provides a new paradigm with high efficiency and safety for tumor treatment.

The invention relates to a medicinal and edible compound extract for improving myelosuppression of a tumor patient after chemotherapy, and a preparation method and application of the medicinal and edible compound extract. The compound extract is extracted from a composition at least comprising the following raw material medicines in parts by weight: 0.9-10 parts of tricholoma matsutake, 0.9-10 parts of mulberry and 0.5-10 parts of rhizoma polygonati. The raw material medicine composition further comprises the following raw material medicines in parts by weight: 0.7-10 parts of longan, 0.5-10 parts of pericarpium citri reticulatae, 0.5-10 parts of scorched hawthorn fruit, 0.5-10 parts of fructus amomi, 1.1-10 parts of cordyceps sinensis rice flour and 2.5-15 parts of rice peptide. The selected raw material medicines are all medicinal and edible components, do not cause adverse effects on liver and kidney functions and gastrointestinal tracts of eaters, and are high in safety and high in patient acceptance degree. Effect verification results show that the mulberry compound extract has an improvement effect on the side effect of bone marrow suppression of tumor patients, especially in the early stage, no related adverse reaction is found, and a safe and effective treatment choice is provided for bone marrow suppression.

The invention provides a traditional Chinese medicine composition for treating myelosuppression. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 45-55 parts of astragalus membranaceus, 20-30 parts of glossy privet fruit, 15-25 parts of rubia yunnanensis, 45-55 parts of caulis spatholobi, 20-30 parts of polygonum cuspidatum, 15-25 parts of radix ranunculi ternati and 25-35 parts of wild buckwheat. The invention further provides a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has the effects of strengthening the body resistance, tonifying deficiency and enhancing the immune function of a patient, improves the tolerance of a tumor patient to an anti-tumor drug, and is particularly suitable for prognosis treatment of a lung cancer patient with deficiency of both qi and yin. The traditional Chinese medicine composition can improve the myelosuppression symptom after anti-tumor medicine treatment (such as chemoradiotherapy), has the effects of increasing the capacity of white blood cells, red blood cells, blood platelets, bone marrow DNA, hematopoietic stem cells or / and hematopoietic tissues and treating cancer fatigue and / or consumptive disease, and plays the optimal effect at a low dosage. The preparation method is simple and is suitable for large-scale production, popularization and application.

The application discloses a chromone spiro compound, a preparation method and application thereof, and the chromone spiro compound is shown as formula I. The compound has selective CDK4 / 6 inhibitory activity, can relieve and / or treat myelosuppression caused by chemotherapy, improve weight loss caused by chemotherapy and improve survival rate, and has good drug safety. The compound has simple preparation method, is convenient for large-scale production, and has great application prospect.

The present invention provides a kind of Chinese medicine preparation for preventing and treating myelosuppression after chemotherapy, relates to the field of Chinese medicine pharmacy, the Chinese medicine preparation is made of 1-15 parts of antler glue, 1-10 parts of astragalus, 1-10 parts of cinnamon twig, 1-10 parts of notoginseng, 1-10 parts of immature bitter orange, 1-10 parts of rhizoma anemarrhenae, 1-10 parts of phellodendron, and the Chinese medicine preparation of the present invention has the effects such as replenishing qi and blood, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain. The Chinese medicine preparation of the present invention can reverse the myelosuppression caused by 5-FU chemotherapy by improving the peripheral blood count and bone marrow pathological damage of chemotherapy mice. In addition, the Chinese medicine preparation of the present invention can improve the 5-FU chemotherapy effect by increasing the 5-FU tumor inhibition rate, suppressing tumor weight, tumor volume and promoting tumor tissue necrosis. The Chinese medicine preparation of the present invention and the chemotherapy drug 5-FU are used in combination to have a certain synergistic and toxicity-reducing effect, and are expected to be developed as a medicine for preventing and treating myelosuppression after chemotherapy.

The present invention provides a method and related equipment for early warning of myelosuppression risk caused by treatment, which are applied to the field of data processing technology. The present application processes the multimodal data information of a target user to generate a target physiological state prediction factor; processes the target user's serum marker characteristic information to generate a myelosuppression influencing factor; processes the target user's lifestyle information to generate a myelosuppression risk adjustment factor; processes the myelosuppression influencing factor and the myelosuppression risk adjustment factor to generate dynamic risk parameter information for the target user; and processes the target physiological state prediction factor and the target user's dynamic risk parameter information based on a target high-dose methotrexate myelosuppression risk prediction model to generate a myelosuppression risk value and a bone marrow transplant risk level.

The invention discloses a wolfberry-astragalus compound polysaccharide with an anti-myelosuppression effect as well as a preparation method and application of the wolfberry-astragalus compound polysaccharide. The wolfberry-astragalus compound polysaccharide is prepared by adopting a process of separately extracting wolfberry polysaccharide and astragalus polysaccharide and then mixing, the total sugar content is 70-80%, the uronic acid content is 10-14%, and the wolfberry-astragalus compound polysaccharide has specific molecular weight distribution and monosaccharide composition characteristics. Animal experiment results show that the wolfberry and astragalus compound polysaccharide can significantly improve peripheral hemopenia of myelosuppression mice induced by cyclophosphamide, promote recovery of the number of leukocytes, lymphocytes, monocytes and neutrophils, and effectively reverse weight loss caused by chemotherapeutic drugs. The wolfberry-astragalus compound polysaccharide provided by the invention is high in safety and remarkable in anti-myelosuppression effect, and can be used for preparing medicines or functional preparations for improving myelosuppression related diseases.

The invention relates to the technical field of pharmaceutical preparations, in particular to a traditional Chinese medicine composition for invigorating qi, blood, yin and yang and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials: tortoise-shell glue, deer-horn glue, donkey-hide gelatin, ginseng, astragalus membranaceus, codonopsis pilosula and fructus lycii, and is prepared by fermenting the raw materials, and the mass ratio of the tortoise-shell glue to the deer-horn glue to the donkey-hide gelatin to the ginseng to the astragalus membranaceus to the codonopsis pilosula to the fructus lycii is 1: (0.5-2): (0.5-2): (1-4): (2-5): (2-6): (2-6). The fermented product obtained by fermenting the medicine raw materials through probiotics can be used for treating qi-blood yin-yang deficiency syndromes such as fatigue, myocardial ischemia, cerebral hypoxia and kidney essence deficiency and / or treating and preventing leukopenia caused by myelosuppression and / or DNA (deoxyribonucleic acid) reduction after radiation and / or hypoimmunity and plateau hypoxia. The effects of preventing sudden cardiac death and the like are obvious.

The present invention relates to CARs that are specific for CD45, and cells comprising said CARs and their use in the treatment of disease, for example for myeloablation or for treating haematological cancer.

This invention discloses a yam vesicle nanomaterial, its preparation method, and its application for reducing the toxicity of radiotherapy for breast cancer. It belongs to the field of biomedical technology. The method includes adding PBS to the yam at a weight-to-volume ratio of 1:3 for juicing, sieving the yam juice, centrifuging the resulting yam filtrate at low speed to obtain supernatant A, centrifuging supernatant A at medium speed to obtain supernatant B, centrifuging supernatant B at ultra-high speed, resuspending the precipitate in PBS, and obtaining the yam vesicle nanomaterial. In this invention, the yam vesicle nanomaterial uses yam as raw material. The obtained yam vesicle nanomaterial has natural bone marrow targeting properties, requires no additional modification, and can spontaneously accumulate in the bone marrow after intravenous injection, specifically protecting the hematopoietic system. It can also simultaneously prevent the decrease in white blood cells, red blood cells, and platelets caused by radiotherapy, comprehensively alleviating the bone marrow suppression side effects of radiotherapy without affecting the efficacy of tumor radiotherapy.

The invention discloses application of bilobalide in inhibiting migration and invasion of ovarian cancer cells, and relates to the technical field of biological medicines. Application of bilobalide in preparation of drugs for inhibiting migration and invasion of ovarian cancer cells; the concentration of the bilobalide is 5 [mu] M to 40 [mu] M. In the application of the bilobalide, the bilobalide shows an obvious growth inhibition effect on ovarian cancer cells and has no obvious influence on the survival rate of normal ovarian cells; in a concentration range of 5-40 [mu] M, bilobalide shows dose dependence on activity inhibition of SKOV3 and ID-8 cells, but has small influence on IOSE80 cells, and shows a good safety window; compared with a traditional chemotherapeutic drug, the bilobalide as a natural compound has better biocompatibility, and is expected to be capable of remarkably relieving common toxic and side effects such as myelosuppression and liver and kidney function impairment in clinical application.

The invention provides a multi-vitamin traditional Chinese medicine composition for preventing and treating myelosuppression. The multi-vitamin traditional Chinese medicine composition comprises the following components in parts by weight: 25-35 parts of Chinese dates, 18-25 parts of suberect spatholobus stems, 6-15 parts of fructus psoraleae, 6-15 parts of glossy privet fruits and 10-20 parts of acanthopanax roots. According to the multi-dimensional traditional Chinese medicine composition for preventing and treating myelosuppression, the goals of bone marrow protection and multi-line blood cell rising can be planned as a whole, and the myelosuppression can be prevented and treated in a multi-dimensional manner. The invention further provides a multi-dimensional herbal preparation for preventing and treating myelosuppression and application of the multi-dimensional traditional Chinese medicine composition for preventing and treating myelosuppression in preparation of myelosuppression drugs.

The invention discloses an anti-osteosarcoma combined pharmaceutical composition and application thereof. The combined pharmaceutical composition comprises a TNF alpha inhibitor and a chemotherapeutic drug. According to the invention, the TNF alpha inhibitor and the traditional chemotherapeutic drug are combined for use for the first time to resist osteosarcoma, so that the purposes of synergistic tumor inhibition, toxicity reduction and sensitization are achieved. By intervening a neglected chemotherapy side reaction pathway of tumor-liver axis, tumor-derived extracellular vesicles are blocked to induce Kupffer cells to release TNF alpha, liver lipid droplet deposition is reduced, and expression (including Cyp1a2, Cyp2b10, Cyp3a11 and the like) of CYP metabolic enzymes is recovered, so that the metabolic capability of the liver to chemotherapy drugs is improved, and toxic and side effects are reduced. From the perspective of chemotherapy tolerance and toxic and side effect control, cardiotoxicity and myelosuppression are remarkably reduced, the overall tolerance to a chemotherapy regimen is improved, and a safer and more efficient strategy is provided.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for relieving myelosuppression after chemotherapy, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises 18-30 parts of deer heart blood powder, 10-15 parts of ginseng, 4-10 parts of radix polygonati officinalis, 4-10 parts of semen ziziphi spinosae, 18-25 parts of semen coicis, 4-10 parts of fructus citri, 8-15 parts of poria cocos and 8-15 parts of radix puerariae, can relieve the bone marrow injury form after chemotherapy, promotes peripheral blood circulation and immune cell recovery, and shows the effect of relieving bone marrow suppression after chemotherapy. The traditional Chinese medicine composition is free of toxic and side effects, easy to absorb, high in safety after long-term use and free of obvious drug resistance, and has a good prospect in preparation of drugs for conditioning bone marrow functions after chemotherapy.

The present invention relates to a promoting of hematological recovery when using chemotherapy. It has been observed that a Clever-1 inhibitor can be used for the treatment of cancer together with chemotherapy to prevent and treat chemotherapy-induced suppression of the bone marrow and / or chemotherapy-induced lymphopenia and neutropenia.

The invention discloses an application of a fresh astragalus source vesicle in preparation of chemotherapy adjuvant drugs. The invention provides and verifies that the fresh astragalus source vesicles have dual effects of enhancing the chemotherapy curative effect and relieving myelosuppression caused by chemotherapy for the first time, and can be used for a novel adjuvant therapy strategy. Meanwhile, the fresh radix astragali source vesicles are derived from medicinal and edible radix astragali, so that the fresh radix astragali source vesicles have the characteristics of high safety and low clinical risk, and a solid foundation is laid for subsequent clinical transformation.

The invention relates to the field of intelligent management, in particular to a bone marrow suppression personalized management platform and equipment based on self-report outcome of a patient. The functional service layer is used for providing functional services for a medical care terminal and a patient terminal, and the medical care terminal uploads resource information, uploads questionnaires and records an overall chemotherapy appointment list; the patient end can browse resource information, fill in questionnaires and upload self-inspection data; and storing the functional service layer data. And the interaction processing layer is used for realizing a multi-dimensional interaction function, and the interaction function comprises patient and patient health interaction, nurse and patient tracking follow-up visit, man-machine intelligent suggestion, doctor and patient question and answer and storage of data of the interaction processing layer. And the intelligent control layer performs intelligent analysis based on the data of the function service layer, the data of the interaction processing layer and the clinical data of the patient in the hospital database, and provides alarm, reminding and appointment functions for the patient terminal. Therefore, the problems that in the tumor chemotherapy intermission period, a patient is prone to CIM and infection, and the re-admission rate is high are solved.

The invention discloses a diagnosis and treatment target device for cytophagic lymphocytosis. The device comprises a detection module, a detection module and a control module, wherein the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2 in a patient sample of a current patient; the detection module is used for detecting the expression quantity of four genes, namely CCR2, CDKN1A, TNFSF10 and TP53INP2; the analysis module is used for carrying out difference analysis on the expression quantity and the expression quantity of a healthy control group to obtain a molecular characteristic spectrum related to the HLH; the diagnosis typing treatment module is used for performing diagnosis typing on the current patient according to a difference mode of the molecular characteristic spectrum and treating according to a diagnosis typing result, so that serious treatment toxicity such as myelosuppression and liver and kidney injury of a traditional chemotherapy regimen can be reduced, the safety and effectiveness of clinical treatment of the patient are improved, and higher specificity and accuracy are achieved; a foundation is laid for developing a novel diagnostic tool, and a direct and feasible candidate scheme and a theoretical basis are provided for developing a high-efficiency and low-toxicity HLH new therapy.

The invention provides a spleen-tonifying and detoxifying traditional Chinese medicine composition as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises a formula A and a formula B. The traditional Chinese medicine composition has a comprehensive conditioning effect and can relieve chemotherapy side effects, improve intestinal flora distribution, promote intestinal health, enhance the chemotherapy effect and improve the disease control rate. Wherein the formula A focuses on tonifying spleen and regulating qi, and improving nausea, vomiting and other symptoms at the initial stage of chemotherapy, and the formula B is added with medicines for clearing away heat and toxic materials and promoting blood circulation to remove blood stasis on the basis, is suitable for patients with myelosuppression with cancer toxicity residue, and strengthens the effects of clearing away heat and toxic materials and removing stasis; the composition has a multi-target action mechanism, and through the combined action of multiple ways, the treatment effect is enhanced, and the side effect is reduced.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The application provides a derivative of plinabulin with the structure of formula (I), which is used for anti-tumor, preventing chemotherapy-induced neutropenia and preventing chemotherapy-induced myelosuppression. In the field of cancer treatment, the two derivatives provided by the application have lower toxic side effects under the similar therapeutic effect of plinabulin, have stronger therapeutic effect and higher therapeutic index under the similar toxic side effects, have similar ability of preventing neutropenia and lower toxic side effects compared with plinabulin, have better therapeutic effect than the combination of the commercialized white blood cell increasing drug Neulasta and plinabulin, and can significantly increase the number of various blood cells when combined with a chemotherapy drug. The derivatives provided by the application have wide application prospects in anti-tumor treatment, prevention of neutropenia and prevention of myelosuppression.